Navigation Links
AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
Date:2/17/2011

ALISO VIEJO, Calif., Feb. 17, 2011 /PRNewswire/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced the promotion of Gregory J. Flesher to the position of Senior Vice President of Corporate Development and Chief Business Officer.  In this role, Mr. Flesher will oversee corporate strategy, business development, program management, and business operations.

"Greg has shown exceptional leadership over the past several years and has played a key role in the transformation of AVANIR into a commercial-stage organization," said Keith Katkin, President and Chief Executive Officer.  "His broad pharmaceutical background in business development, sales and marketing, and research and development provides a strong foundation which will help AVANIR grow into a successful CNS company.  I look forward to Greg's continued contributions to the executive management team."

Mr. Flesher has over 16 years of experience in the pharmaceutical industry.  He was previously Vice President of Business Development for AVANIR, with responsibility for business transactions, intellectual property, and NUEDEXTA™ lifecycle planning.  Prior to joining the Company, he held various positions of increasing responsibility at InterMune Inc., Amgen Inc., and Eli Lilly and Company.

Mr. Flesher graduated from Purdue University with a degree in Biology and has completed his doctorate coursework in Biochemistry and Molecular Biology at Indiana University School of Medicine.

About AVANIR Pharmaceuticals, Inc.

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about AVANIR, please visit www.avanir.com.

AVANIR™ and NUEDEXTA™ are trademarks owned by AVANIR Pharmaceuticals, Inc.

©2011 AVANIR Pharmaceuticals, Inc. All Rights Reserved.


'/>"/>
SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
2. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
3. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
4. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
6. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
7. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
8. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
9. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
10. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
11. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... vaccines market to grow at a CAGR of 6.83% during the ... the growth prospects of the global travel vaccines market for 2016-2020. ... from the sales of various vaccines administered to actively immunize meningococcal ...
(Date:12/9/2016)...  Forge Therapeutics, Inc. today announced a strategic ... TecDAX, ISIN: DE0005664809) to advance its novel Gram-negative ... bacterial infections including those caused by drug resistant ... antibacterial target for more than the past 15 ... points has hampered its progress. Forge has been ...
(Date:12/8/2016)... Australia Glaucoma Surgery Devices Market Outlook ... "Australia Glaucoma Surgery Devices Market Outlook to 2022", ... Surgery Devices market. The report provides value, in ... average prices (USD) within market segement - Glaucoma ... shares and distribution shares data for each of ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... JENNERSVILLE, Pa. (PRWEB) , ... December 08, 2016 ... ... Penn Medicine Southern Chester County, a Property owned by an affiliate of Seavest, ... 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had joined the Pharmaceutical ... a non-profit organization to unite pharmaceutical and healthcare companies that share a vision ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):